Singulair Litigation at The Lanier Law Firm
On March 27, 2008, the U.S. Food and Drug Administration (FDA) announced an investigation into a possible association between patient suicide and the use of Singulair asthma medication. The announcement was made after reports of suicide among Singulair users. In addition to the reports of suicide, the FDA also is investigating reports of mood and behavior changes among Singulair users.
Singulair Background Information
Singulair is used to treat asthma and allergy symptoms like sneezing and itchy/runny nose. The drug is manufactured by pharmaceutical giant Merck, the same company that made the controversial painkiller VIOXX® before it was withdrawn from the market. Since Singulair was approved for sale in this country in 1998, it has been prescribed to millions of U.S. citizens. Last year, the drug accounted for $4.3 billion in sales for Merck.
Problems Caused by Singulair
During the past year alone, Merck has updated the prescribing information and patient information for Singulair four separate times to include the possible adverse side effects of tremors, depression, suicidality (suicidal thinking and behavior), and anxiousness. The FDA investigation follows multiple reports of suicides among Singulair patients.
If you or a loved one has used Singulair and suffered adverse side effects, including suicidal thoughts or behavior, please contact us for a free evaluation.
Singulair Information:
